论文部分内容阅读
恶性肿瘤患者由于肿瘤本身因素或化疗因素,往往伴有不同程度的贫血,本文尝试大剂量促红细胞生成素(EPO)静脉给药治疗肿瘤性贫血,获得满意的临床效果,现报告如下。1资料与方法1.1临床资料将本院2015年3月~2016年3月肿瘤科治疗后出现中度及以上贫血并转入本科的126例患者作为研究对象,所有患者均参照肿瘤性贫血标准诊断。其中,男67例、女59例;年龄24~86岁、平均58.8岁。肺癌31例,胃癌28例,结直肠癌
Patients with malignant tumors are often accompanied by different degrees of anemia due to tumor factors or chemotherapy factors. In this article, large doses of erythropoietin (EPO) are administered intravenously to treat tumorous anemia and satisfactory clinical results are obtained. The report is as follows. 1 Materials and Methods 1.1 Clinical data The 126 patients with moderate or above anemia after oncology treatment in our hospital from March 2015 to March 2016 were included in the study. All patients were diagnosed according to standard criteria of tumor anemia. . Among them, there were 67 males and 59 females; aged 24-86, with an average of 58.8. 31 cases of lung cancer, 28 cases of gastric cancer, colorectal cancer